In-Vitro Colorectal Cancer Screening Tests Market Expected To Trigger A Revenue To USD 840.5 Million By 2022 : Grand View Research Inc.
San Francisco, 10 July 2019: The Report In-Vitro Colorectal Cancer Screening Tests Market Analysis By Product (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Tumor M2-PK Stool Test, Transferrin Assays, Methylated Gene Testing, Panel DNA Tests) And Segment Forecasts to 2022 The global market for In-Vitro Colorectal Cancer Screening Tests is expected to reach USD 840.5 million by 2022, according to a new study by Grand View Research, Inc. Increasing incidences of colorectal cancer and the development of novel CRC screening tests employing methods of genetic screening are some primary factors expected to drive market growth over the forecast period. The implementation of government regulations introducing compulsory application of cancer screening tests, introduction of minimally invasive tests which screen for CRC using DNA and genomic biomarkers, and